Previous Close | 2.1100 |
Open | 2.1000 |
Bid | 2.1000 x 1000 |
Ask | 2.1100 x 900 |
Day's Range | 2.0850 - 2.1350 |
52 Week Range | 1.6000 - 4.3700 |
Volume | |
Avg. Volume | 379,306 |
Market Cap | 115.821M |
Beta (5Y Monthly) | 1.48 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.1780 |
Earnings Date | Mar 13, 2023 - Mar 17, 2023 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | Oct 31, 2014 |
1y Target Est | 17.50 |
National Healthcare Security Administration Adds NUZYRA to NRDL for Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure InfectionsBOSTON, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that China’s National Healthcare Security Administration (NHSA) has added the intravenous (IV) formulation of NUZYRA® (omadacycline) to the country’s National Reimbursement Drug List (NRDL) for treatment of community-acquir
Total Procurement-related Revenue Recognition of $38.1 Million to Paratek in December 2022Procurement Triggered by Positive Top-Line Data from Pilot Efficacy Study of NUZYRA for the Treatment of Pulmonary Anthrax Announced in December BOSTON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK) today announced the receipt of a $36.4 million milestone payment associated with the second procurement of NUZYRA® (omadacycline) under the company’s Project BioShield contract w
If you want to know who really controls Paratek Pharmaceuticals, Inc. ( NASDAQ:PRTK ), then you'll have to look at the...